NMN projects of Yikelai Pharmaceutical and Kangjie Biotechnology pass EIA

Summary: Two NMN projects passed EIA — Yikelai Pharmaceutical's technology upgrading project of 100 t/a sitagliptin, 100 t/a nicotinamide mononucleotide (NMN) and 90 t/a 2-R-BOC-butyric acid, and Kangjie Biotechnology's expansion project of 20 ...

Vitamins China E-News 202108

www.cnchemicals.com